Author Archives: Lu Rahman

#Biologics / Biotechnology #Concarlo Holdings #Oncology

US biotech start-up set to have huge impact on breast cancer treatment landscape

Backed by more than 20 years of research and development expertise, Concarlo Holdings is developing diagnostics and therapeutics that could have huge impact for metastatic breast cancer patients. Lu Rahman finds out more. Stacy Blain, Co-Founder, Concarlo Holdings, wants to change the conversation around breast cancer. This biotechnology start-up whose… Read More

#Cancer Research #Exclusive Content

#Biologics / Biotechnology #Drug discovery #Japan #NGS #PCR

Big in Japan: SPT Labtech spots biotech growth

SPT Labtech recently opened a new office to maximise on Japanese biotech growth. Lu Rahman caught up with Director Masahiro Matsushita, to find out about the region and the opportunities for drug discovery.   LR: Tell me about the company’s experience in the Japanese biotech market in Japan – how… Read More

#Market Reports

#AI / data analytics / healthtech / informatics #Biopharma #Clinical trials #Covid-19 #Drug discovery #Therapeutics

Sitting down with…Biorelate

Daniel Jamieson is the CEO and Founder of Biorelate, a biomedical curation company that aims to accelerate insight and innovation in drug discovery. Lu Rahman spoke to him about his vision for the business, how COVID-19 has affected the landscape and the technology behind his drug discovery success. Biorelate was… Read More

#Opinion

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

Social distancing shows us we’re better together

What a time to be involved in drug discovery. While COVID-19 has of course created unprecedented conditions on a global scale, it has also highlighted the extent to which this sector offers depth of knowledge, skill and innovation. It is a pleasure to learn more about the market – both… Read More

#Opinion

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Regulatory

Automating regulatory data to drive discovery

The multi-year process of drug discovery and development creates huge silos of data and information. Extracting and combining information can be a significant overhead, resulting in potential for delay and error. Iperion’s Duncan van Rijsbergen provides practical recommendations to help companies create high quality, consistent data that may be shared… Read More

#Exclusive Content #Regulatory

#Antibodies #Covid-19 #NIAID

Genetic and immunologic reasons explain severe COVID-19 cases

New findings by scientists at the National Institutes of Health and their collaborators help explain why some people with COVID-19 develop severe disease. The findings also may provide the first molecular explanation for why more men than women die from COVID-19. The researchers found that more than 10% of people… Read More

#Covid-19

#Covid-19 #UCL #Vaccines

A fifth of UK people won’t to get vaccinated against COVID-19

A fifth (22%) of people have said that when a COVID-19 vaccine is approved, they’re unlikely to get it, with 10% of people saying they were ‘very unlikely’ to get vaccinated, find UCL researchers as part of the COVID-19 Social Study. Only half (49%) of people reported being ‘very likely’… Read More

#Covid-19

#Covid-19 #Therapeutics

Exercise hormone may modulate genes linked with novel coronavirus

A study conducted by researchers at São Paulo State University (UNESP) suggests that irisin, a hormone secreted from muscles in response to exercise, could have a therapeutic effect on COVID-19 patients. When they analysed adipose cell gene expression, the researchers found that irisin modulated genes associated with replication of the… Read More

#Covid-19

#Covid-19 #Drug targets #Manchester University

Monocytes may be therapeutic target for a COVID-19 treatment

White blood cells called monocytes released into the blood from bone marrow have abnormal features in people who have COVID-19. This is according to a new study by University of Manchester immunologists at the Lydia Becker Institute. The team from the Coronavirus Immune Response and Clinical Outcome (CIRCO) consortium says… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Covid-19 #Drug candidates #Drug development #MS #Therapeutics

New for old: the value behind drug repurposing  

Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially?  More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly, drug… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#AstraZeneca #Clinical trials #Covid-19 #Drug discovery #Therapeutics #Vaccines

Where are the opportunities in global drug discovery?

With COVID-19 taking centre stage in global drug discovery, Lu Rahman looks at opportunities ahead for the sector and where attention might be focussed going forward.  It is clear from the current pandemic that opportunities arise within drug discovery and development when we don’t always expect them. COVID-19 has created… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#Covid-19 #Drug development #Drug discovery #Liverpool

Creating a world leading infection R&D hub in the UK

As the world is rocked by one of the greatest healthcare challenges in living memory, how we treat infectious diseases is becoming one of the key medical questions of our age. Hannah Randles, Health and Life Sciences Champion at Liverpool City Region’s Growth Platform explains how the region’s infectious diseases… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#DNAGenotek #Metabolomics #Metabolon #Precision medicine

Why metabolomics has the potential to transform diagnosis and treatment

Lu Rahman speaks to key members of Metabolon on the company’s pioneering work in metabolomics including its innovative collaborations with DNAGenotek and the Institute for Systems Biology. “Metabolon has built an unrivalled global biochemical profiling platform capable of providing metabolite data of unsurpassed quality and coverage,” says Brian Keppler, PhD, Director,… Read More

#Exclusive Content #Opinion

#Assays #Drug discovery #Microfluidics #Molecular Devices #Protein Fluidics

The workflow game-changer: combined technologies for efficiency

Oksana Sirenko, Senior Scientist, Molecular Devices and Evan Cromwell, President & CEO, Protein Fluidics, explain the benefits of automated organoid assays with microfluidics and 3D imaging. Microfluidic flowchip technology combined with three-dimensional (3D) imaging is a powerful duo poised to change the future of drug discovery and development. The integration… Read More

#Exclusive Content

#Assay development optimisation & technology #Corning Life Sciences #Tissue chips

Why we should be interested in human tissue chips

Dr. Kacey Ronaldson-Bouchard (pictured) explains why adapting cell-based assays from suspension cells to 2D culture, 3D culture, and beyond to ‘patient in a dish’ systems is not an exercise undertaken lightly. However, the effort pays off on many levels.  Our incomplete understanding of human biology and the limited potential for human… Read More

#Exclusive Content

#Biologics #Drug development #Erythropoietin #Gene therapy #SCIEX

The power of precision to keep biologics safe and effective

How do we know the medicines we take are safe and effective from batch to batch? Medicinal products like erythropoietin and gene therapies can be very challenging to quality control. Dr Mark Lies, Global Business Manager of Capillary Electrophoresis, SCIEX describes how capillary electrophoresis is being applied to address these… Read More

#Exclusive Content